Table 1.
Sample characterization.
| n | % | ||
|---|---|---|---|
| Sex | Female | 34 | 44.2 |
| Male | 43 | 55.8 | |
| Illness | Malignant | 59 | 76.6 |
| Not Malignant | 18 | 23.4 | |
| BMI | Normal | 57 | 74 |
| Underweight | 5 | 6.4 | |
| Obese | 15 | 19.4 | |
| NRI | Severe | 77 | 100 |
| Moderate | 0 | 0 | |
| Mild | 0 | 0 | |
| No risk | 0 | 0 | |
| Albumin | >3.5 | 67 | 87 |
| <3.5 | 10 | 12.9 | |
| Progenitor cell source | Bone Marrow | 52 | 67.5 |
| Peripheral blood | 24 | 31.2 | |
| Umbilical cord | 1 | 1.3 | |
| Related Donor | Related | 62 | 80.5 |
| Unrelated | 15 | 19.5 | |
| Conditioning Regimen | Myeloablative | 50 | 64.9 |
| Non-myeloablative | 5 | 6.5 | |
| Reduced Intensity | 22 | 28.6 | |
| GvHD | Yes | 28 | 36.4 |
| No | 49 | 63.6 | |
| GvHD site | Skin | 10 | 13.0 |
| Mouth | 2 | 2.6 | |
| Gastrointestinal tract | 2 | 2.6 | |
| Liver | 1 | 1.3 | |
| ≥2 sites | 13 | 16.9 | |
| Outcome | Remission | 55 | 71.4 |
| Others* | 22 | 28.6 |
GvHD, graft-versus-host disease; BMI, body mass index; NRI, nutritional risk index;.
⁎
Note: Other outcomes included relapse and death.